Federated Hermes Inc. Has $1.69 Million Stake in Enovis Co. (NYSE:ENOV)

Federated Hermes Inc. cut its stake in Enovis Co. (NYSE:ENOV) by 7.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 37,393 shares of the company’s stock after selling 3,127 shares during the period. Federated Hermes Inc. owned approximately 0.07% of Enovis worth $1,690,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in ENOV. American Century Companies Inc. boosted its position in shares of Enovis by 78.6% during the second quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock worth $68,337,000 after buying an additional 665,208 shares during the period. Wells Fargo & Company MN boosted its position in Enovis by 907.7% during the 4th quarter. Wells Fargo & Company MN now owns 559,430 shares of the company’s stock worth $31,339,000 after acquiring an additional 503,913 shares during the last quarter. UBS Group AG grew its stake in shares of Enovis by 1,060.8% during the 4th quarter. UBS Group AG now owns 333,510 shares of the company’s stock worth $18,683,000 after acquiring an additional 304,779 shares in the last quarter. Boston Partners raised its holdings in shares of Enovis by 206.5% in the first quarter. Boston Partners now owns 295,969 shares of the company’s stock valued at $18,455,000 after purchasing an additional 199,411 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of Enovis by 100.6% in the first quarter. Janus Henderson Group PLC now owns 378,020 shares of the company’s stock worth $23,606,000 after purchasing an additional 189,584 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ENOV shares. Needham & Company LLC decreased their target price on shares of Enovis from $82.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Evercore ISI lowered their target price on Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Finally, JPMorgan Chase & Co. reduced their price target on Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $69.13.

Enovis Trading Down 3.0 %

Shares of NYSE:ENOV opened at $43.65 on Friday. Enovis Co. has a 52-week low of $39.98 and a 52-week high of $65.03. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 2.26. The company has a market capitalization of $2.39 billion, a P/E ratio of -29.10 and a beta of 1.92. The company has a 50-day simple moving average of $44.73 and a 200 day simple moving average of $50.05.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.03. The company had revenue of $525.20 million during the quarter, compared to analysts’ expectations of $525.99 million. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. The business’s revenue was up 22.6% on a year-over-year basis. During the same period last year, the firm posted $0.61 earnings per share. Sell-side analysts forecast that Enovis Co. will post 2.7 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.